Stock 600332 GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Shanghai S.E.

Equities

600332

CNE000001733

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
31.25 CNY -0.22% Intraday chart for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited +3.03% +9.27%
Mar. 18 Baiyunshan Pharmaceutical's 2023 Profit Rises 2% MT
Mar. 15 Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Announces Final Ordinary Dividend for the Year Ended 31 December 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The company is in a robust financial situation considering its net cash and margin position.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • The company shows low valuation levels, with an enterprise value at 0.17 times its sales.
  • The company appears to be poorly valued given its net asset value.
  • The company is one of the best yield companies with high dividend expectations.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED Stock Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
+9.27% 6.65B -
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.17% 562B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.62% 358B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.12% 322B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.06% 297B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.45% 219B
B+
NOVARTIS AG Stock Novartis AG
+6.04% 199B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-10.51% 196B
A+
PFIZER, INC. Stock Pfizer, Inc.
-11.64% 149B
C+
AMGEN INC. Stock Amgen Inc.
-6.98% 146B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 874 Stock
  4. 600332 Stock
  5. Ratings Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited